Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Receives Consensus Rating of “Hold” from Analysts

Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) have been assigned an average rating of “Hold” from the five analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $5.00.

A number of research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Citius Pharmaceuticals in a research report on Wednesday, August 19th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a report on Wednesday, June 24th. Wall Street Zen lowered Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Finally, Citigroup reissued a “buy” rating on shares of Citius Pharmaceuticals in a report on Wednesday, August 19th.

Citius Pharmaceuticals Stock Up 5.0%

Citius Pharmaceuticals stock opened at $0.59 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.40 and a debt-to-equity ratio of 0.08. Citius Pharmaceuticals has a 1-year low of $0.47 and a 1-year high of $2.19. The firm’s fifty day simple moving average is $0.59 and its 200-day simple moving average is $0.66. The company has a market capitalization of $16.14 million, a P/E ratio of -0.35 and a beta of 1.00.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.02. Sell-side analysts forecast that Citius Pharmaceuticals will post -2.03 earnings per share for the current fiscal year.

Institutional Trading of Citius Pharmaceuticals

An institutional investor recently bought a new stake in Citius Pharmaceuticals stock. BlackRock Inc. bought a new stake in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 69,850 shares of the company’s stock, valued at approximately $42,000. BlackRock Inc. owned approximately 0.25% of Citius Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.